Literature DB >> 29656841

From phaeohyphomycosis to disseminated chromoblastomycosis: A retrospective study of infections caused by dematiaceous fungi.

E Thomas1, A Bertolotti2, A Barreau1, J Klisnick2, P Tournebize3, G Borgherini2, N Zemali1, J Jaubert1, G Jouvion4, S Bretagne5, S Picot6.   

Abstract

OBJECTIVE: Infections caused by dematiaceous fungi are more common in tropical and subtropical areas. We aimed to describe the clinical, microbiological and therapeutic aspects of case patients diagnosed at a University Hospital located on an Indian Ocean island. PATIENTS AND METHODS: We performed an observational retrospective study of infections caused by dematiaceous fungi diagnosed at the University Hospital of Saint-Pierre, Reunion, from 2000 to 2015. Mycological identifications were performed at the National Reference Center for Invasive Mycosis and Antifungal Agents (Paris).
RESULTS: The review of clinical and microbiological data of 11 patients identified revealed that five were infected by dematiaceous fungi. Two had cutaneous phaeohyphomycosis, two had cerebral phaeohyphomycosis and one had cutaneous chromoblastomycosis with brain and potentially medullary dissemination. Skin lesions and cerebral abscesses were quite varied.
CONCLUSION: Infections caused by dematiaceous fungi are rare. Medullary and brain localizations are extremely rare, especially for chromoblastomycosis. Cutaneous manifestations of phaeohyphomycosis are varied; diagnosis is thus more difficult. It is therefore important, when confronted with a chronic tumor-like lesion in endemic areas, to perform a biopsy for pathology and fungal culture. While surgical excision is not always sufficient, medical treatment of these infections is not standardized, but relies on an azole, which can be associated with another antifungal agent.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Abcès cérébral; Antifongiques; Antifungal agents; Brain abscess; Chromoblastomycosis; Chromomycose; Dematiaceous; Dématiés; Phaeo-hyphomycose; Phaeohyphomycosis

Mesh:

Year:  2018        PMID: 29656841     DOI: 10.1016/j.medmal.2017.09.011

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  3 in total

1.  Gram stain to the rescue: a case report of cerebral phaeohyphomycosis by Cladophialophora bantiana in an immunocompetent 24-year-old.

Authors:  Perceus Mody; Paul Wada; Karen C Bloch; Michail S Lionakis; Katie D White; Alexander S Maris; Tonya Snyder; Jennifer Steinhauer; Romney Humphries
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

2.  New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.

Authors:  Rowena Alves Coelho; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fernando Almeida-Silva; Gabriela Rodrigues de Souza; Maria Cristina da Silva Lourenço; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Rodrigo Almeida-Paes
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-12       Impact factor: 2.747

3.  CARD9 deficiency predisposing chromoblastomycosis: A case report and comparative transcriptome study.

Authors:  Chen Huang; Weiwei Deng; Yi Zhang; Kai Zhang; Yubo Ma; Yinggai Song; Zhe Wan; Xiaowen Wang; Ruoyu Li
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.